Document:

Form of Common Stock Warrant

 Exhibit 10.14 

THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) OR UNDER ANY APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES
LAWS WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS. 

 

			
	WARRANT NO.                     	  	Date: August     , 2009

WARRANT TO PURCHASE COMMON STOCK 

AutoGenomics, Inc., a Delaware corporation (the “Company”), hereby certifies that
                                         (the
“Holder”), is entitled to purchase, on the terms and conditions contained herein,                          fully
paid, validly issued and nonassessable shares (the “Warrant Shares”) of common stock, no par value, of the Company (the “Common Stock”), at an initial exercise price of $4.00 per Warrant Share, as may be adjusted
pursuant to the terms hereof (the “Exercise Price”). This Warrant has been approved by the Board of Directors of the Company and is issued pursuant to the terms of that certain Subscription Agreement, dated as of the date hereof, by
and between the Company and the Holder (the “Subscription Agreement”). The number of Warrant Shares and the Exercise Price are subject to adjustment as provided in Section 2 below. Capitalized terms used herein not otherwise
defined shall have the meanings set forth in Section 8.1. 
 This Warrant is subject to the following terms and conditions:

 1. Exercisability and Exercise. 

1.1 Method of Exercise. This Warrant may be exercised in whole, or in part, at the option of the Holder at any time and from time
to time from the one (1) year anniversary of the date hereof through and including the five (5) year anniversary of the date hereof, provided that this Warrant may be exercised immediately in connection with a Liquidity Event, by
delivering to the Company payment of the aggregate Exercise Price for the Warrant Shares being purchased by check or wire transfer, together with an executed Notice of Exercise in the form attached as Exhibit I hereto. 

1.2 Effectiveness of Exercise; Procedure. The exercise of this Warrant shall be deemed to have been effected immediately prior to
the close of business on the day on which the Holder delivers the Notice of Exercise to the Company together with payment of the Exercise Price and satisfies all of the requirements of this Section 1. Upon such exercise, the Holder will be
deemed a shareholder of record of the Warrant Shares with all rights of a shareholder (including, without limitation, all voting rights with respect to such Warrant Shares and all rights to receive any dividends with respect

  

 Page 1 

 
to such Warrant Shares). In the event of any exercise of the rights represented by this Warrant, certificates for the shares of Common Stock so purchased shall be delivered to the Holder within a
reasonable time by the transfer agent of the Company by crediting the account of the Holder’s broker with The Depositary Trust Company through its Deposit Withdrawal Agent Commission system if the Company is a participant in such system, and
otherwise by physical delivery to the address specified in the Notice of Exercise. The Company shall not be required to issue fractional shares upon the exercise of this Warrant. In lieu of any fractional share to which the Holder would otherwise be
entitled, the Holder shall be entitled, at its option, to receive either (a) a cash payment equal to the excess of the fair market value, as determined by the Board of Directors of the Company in good faith, for such fractional share above the
Exercise Price for such fractional share (as mutually determined by the Company and the Holder) or (b) a whole share if the Holder tenders the Exercise Price for one whole share. 

2. Adjustments. 

2.1 Reorganizations, Mergers, Recapitalizations and Reclassifications. 

(a) Change of Control. If at any time a Change of Control (as defined below) occurs and, pursuant to the terms of such Change of
Control, shares of common stock of the successor or acquiring corporation, or any cash, shares of stock or other securities or property of any nature whatsoever (including warrants or other subscription or purchase rights) in addition to or in lieu
of common stock of the successor or acquiring corporation (“Other Property”), are to be received by or distributed to the holders of Common Stock of the Company, then the Holder shall have the right thereafter to receive upon
exercise of this Warrant (and this Warrant shall thereafter be exercisable only for) the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and Other Property receivable
upon or as a result of such Change of Control by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Change of Control. In case of any such Change of Control, the successor or acquiring
corporation (if other than the Company) shall expressly assume the due and punctual observance and performance of each and every covenant and condition of this Warrant to be performed and observed by the Company and all the obligations and
liabilities hereunder, subject to such modifications as may be deemed appropriate (as determined in good faith by resolution of the Board of Directors of the Company) in order to provide for adjustments of the Warrant Shares for which this Warrant
is exercisable which shall be as nearly equivalent as practicable to the adjustments provided for in this Section 2.1(a). For purposes of this Section 2.1(a), “common stock of the successor or acquiring corporation” shall include
stock of such corporation of any class which is not preferred as to dividends or assets over any other class of stock of such corporation and which is not subject to redemption. The foregoing provisions of this Section 2.1(a) shall similarly
apply to any successive Change of Control. As used in this Warrant, a “Change of Control” shall mean (i) a transaction or series of transactions (other than an offering of common stock of the Company to the general public
through a registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange
Act of 
  

 Page 2 

 
1934, as amended from time to time (the “Exchange Act”)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its
subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule
13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; or (ii) the consummation by the Company
(whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (A) a merger, consolidation, reorganization or business combination, (B) a sale or other disposition of all or substantially
all of the Company’s assets in any single transaction or series of related transactions or (C) the acquisition of assets or stock of another entity, in each case other than a transaction (1) which results in the Company’s voting
securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Successor Entity (as defined below)) directly or indirectly, at least a majority
of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and (2) after which no person or group beneficially owns voting securities representing 50% or more of the combined
voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this Section 2.1(a)(ii)(C)(2) as beneficially owning 50% or more of combined voting power of the Successor Entity
solely as a result of the voting power held in the Company prior to the consummation of the transaction. As used in this Section 2.1(a)(ii)(C), the “Successor Entity” shall mean, as applicable, the Company or the person that,
as a result of the Change of Control, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company. 

(b) Issuance of Additional Stock below Exercise Price. If the Company issues (or is deemed to have issued pursuant to
Section 2.1(b)(iv) below) after the date hereof (the “Commencement Date”), any Additional Stock without consideration or for consideration per share less than the Exercise Price applicable to any unissued Warrant Shares in
effect immediately prior to the issuance of such Additional Stock, the Exercise Price for the Warrant Shares in effect immediately prior to each such issuance shall automatically be adjusted as set forth in this Section 2.1(b), unless otherwise
provided in this Section 2.1(b) 
 (i) Adjustment Formula. Whenever the Exercise Price applicable to
unissued Warrant Shares is adjusted pursuant to this Section 2.1(b), the new Exercise Price shall be determined by multiplying the Exercise Price for such Warrant Shares then in effect by a fraction, (x) the numerator of which shall be an
amount equal to the sum of (i) the number of shares of Common Stock outstanding (or deemed outstanding pursuant to the provisions of Section 2.1(b)(iv) below) immediately prior to such issuance (the “Fully Diluted Outstanding
Common Stock”), and (ii) the number of shares of Common Stock which the aggregate consideration received by the Company for such issuance would purchase at the applicable Exercise Price in effect immediately prior to the

  

 Page 3 

 
issuance of such Additional Stock for such unissued Warrant Shares; and (y) the denominator of which shall be the number of shares of Fully Diluted Outstanding Common Stock plus the number
of shares of such Additional Stock issued (or deemed issued pursuant to the provisions of Section 2.1(b)(iv) below). 

(ii) No Fractional Adjustments. No adjustment of the Exercise Price for unissued Warrant Shares pursuant to
Section 2.1(b) shall be made in an amount less than one cent per share, provided that any adjustments which are not required to be made by reason of this sentence shall be carried forward and shall be either taken into account in any subsequent
adjustment made prior to three (3) years from the date of the event giving rise to the adjustment being carried forward, or shall be made at the end of three (3) years from the date of the event giving rise to the adjustment being carried
forward. 
 (iii) Determination of Consideration. In the case of the issuance of Common Stock for cash,
the consideration shall be deemed to be the amount paid therefor before deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by the Company for any underwriting or otherwise in connection with the issuance and
sale thereof. In the case of the issuance of Common Stock for consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Company’s
Board of Directors. 
 (iv) Deemed Issuances of Common Stock. In the case of the issuance of options to
purchase or rights to subscribe for Common Stock, securities by their terms convertible into or exchangeable for Common Stock or options to purchase or rights to subscribe for such convertible or exchangeable securities, the following provisions
shall apply for all purposes of this Section 2.1(b): 
 (A) The aggregate maximum number of shares of Common
Stock deliverable upon exercise (assuming the satisfaction of any conditions to exercisability, including without limitation, the passage of time, but without taking into account potential antidilution adjustments) of such options to purchase or
rights to subscribe for Common Stock shall be deemed to have been issued at the time such options or rights were issued and for a consideration equal to the consideration (determined in the manner provided in Section 2.1(b)(iii)), if any,
received, by the Company upon the issuance of such options or rights (without taking into account potential antidilution adjustments) plus the minimum exercise price provided in such options or rights for the Common Stock covered thereby.

 (B) The aggregate maximum number of shares of Common Stock deliverable upon conversion of or exchange
(assuming the satisfaction of any conditions to exercisability, including without limitation, the passage of time, but without taking into account potential 

 

 Page 4 

 
antidilution adjustments) for any such convertible or exchangeable securities or upon the exercise of options to purchase or rights to subscribe for such convertible or exchangeable securities
and subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options or rights were issued and for a consideration equal to the consideration, if any, received by the Company for
any such securities and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum additional consideration, if any, to be received by the Company (without taking into account
potential antidilution adjustments) upon the conversion or exchange of such securities or the exercise of any related options or rights (the consideration in each case to be determined in the manner provided in Section 2.1(b)(iii)). 

(C) In the event of any change in the number of shares of Common Stock deliverable or in the consideration payable to the
Company upon exercise of such options or rights or upon conversion of in exchange for such convertible or exchangeable securities, including, but not limited to, a change resulting from the antidilution provisions thereof, the Exercise Price
applicable to the unissued Warrant Shares, to the extent in any way affected by or computed using such options, right or securities, shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of
Common Stock or any payment of such consideration upon the exercise of any such options or rights or the conversion or exchange of such securities. 

(D) Upon the expiration of such options or rights, the termination of any such rights to convert or exchange or the
expiration of any options or rights related to such convertible or exchangeable securities, the Exercise Price applicable to such unissued Warrant Shares shall, to the extent in any way affected by or computed using such options, rights or
securities or options or rights related to such securities, be recomputed to reflect the issuance of only the number of shares of Common Stock (and convertible or exchangeable securities which remain in effect) actually issued upon the exercise of
such options or rights, upon the conversion or exchange of such securities or upon the exercise of the options or rights related to such securities. 

(E) The number of shares of Common Stock deemed issued and the consideration deemed paid therefor pursuant to
Section 2.1(b)(iv)(A) and Section 2.1(b)(iv)(B) shall be appropriately adjusted to reflect any change, termination or expiration of the type described in either Section 2.1(b)(iv)(C) or Section 2.1(b)(iv)(D). 

(v) No Increase in Exercise Price. Notwithstanding any other provisions of this Section 2.1(b), except to the
limited extent provided for in Section 2.1(b)(iv)(D) and Section 2.1(b)(iv)(E), no adjustment of the Exercise 

 

 Page 5 

 
Price applicable to unissued Warrant Shares pursuant to this Section 2.1(b) (but for the avoidance of doubt expressly excluding Sections 2.1(a) and (c)) shall have the effect of increasing
such Exercise Price above the Exercise Price applicable to such unissued Warrant Shares in effect immediately prior to such adjustment. 

(c) Other Events. If, at any time after the date of this Warrant, (i) the outstanding shares of Common Stock issuable upon
exercise of this Warrant are changed into, or exchanged for, a different number or kind of shares or securities of the Company through a reorganization, merger, recapitalization or reclassification which does not constitute a Change of Control, or
(ii) the number of outstanding shares of such Common Stock is changed through a stock split, reverse stock split, stock dividend, stock consolidation or similar capital adjustment, an appropriate adjustment shall be made by the Board in the
Exercise Price and in the number or kind of shares into which this Warrant is exercisable. In making such adjustments, or in determining that no such adjustments are necessary, the Board may rely upon the advice of counsel and accountants to the
Company. 
 2.2 Notice of Adjustment. Upon the occurrence of each adjustment or readjustment of the Exercise Price or the
number and kind of securities into which this Warrant is exercisable, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such
adjustment or readjustment (including the kind and amount of securities, cash or other property for which this Warrant shall be exercisable and the Exercise Price) and showing in detail the facts upon which such adjustment or readjustment is based.
The Company shall, upon the written request at any time of the Holder, furnish or cause to be furnished to the Holder a certificate setting forth (i) the Exercise Price then in effect and (ii) the number and kind of shares of capital stock
and the amount, if any, of other securities, cash or property which then would be received upon the exercise of this Warrant. 

3. Reservation of Stock. The Company shall at all times have authorized, and reserved for the purpose of the issue upon exercise
of this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of this Warrant. 
 4. Notices
of Record Date, etc. In the event the Company shall take a record of the holders of any of its Common Stock for the purpose (a) of entitling or enabling them to receive any dividend or other distribution, or to receive any right to
subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right; (b) of any capital reorganization of the Company, any reclassification of the stock of the Company or any Change of Control; or
(c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company; then, and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be, (x) the record date
for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (y) the effective date on which such reorganization, reclassification, consolidation, Change of Control, dissolution, liquidation
or winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock of the Company shall be entitled to exchange their shares for 

 

 Page 6 

 
securities or other property deliverable upon such reorganization, reclassification, consolidation, Change of Control, dissolution, liquidation or winding-up. Such notice shall be mailed at least
ten days prior to the record date or effective date for the event specified in such notice. 
 5. Exchange of Warrant.
Upon the surrender by the Holder, properly endorsed, to the Company at the principal office of the Company, the Company will issue and deliver to or upon the order of such Holder, at the Company’s expense, a new Warrant or Warrants of like
tenor, in the name of the Holder or as the Holder may direct, without charge for any issuance or transfer tax or other cost incurred by the Company, calling in the aggregate on the face or faces thereof for the number of shares of capital stock (or
other securities, cash and/or property) then issuable upon exercise of this Warrant. The Company will at no time close its transfer books against the transfer of the Warrant Shares issued or issuable upon the exercise of this Warrant in any manner
which interferes with the timely exercise of this Warrant. 
 6. Replacement of Warrant. Upon receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably
satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. Any such new Warrant executed and delivered shall constitute an
additional contractual obligation on the part of the Company, whether or not the Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone. 

7. Transfer of Warrant. This Warrant and all rights hereunder are transferable, in whole, upon surrender of this Warrant with a
properly executed assignment (in the form of Exhibit II hereto) at the principal office of the Company. However, as a condition to such transfer, either (a) this Warrant must be registered under the Securities Act of 1933, as amended
(the “Act”), and all applicable state securities laws with respect thereto or (b) the Company must first be furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such transfer is
exempt from the registration requirements of the Act. 
 8. Miscellaneous. 

8.1 Certain Definitions. 

“Additional Stock” shall mean any shares of Common Stock issued (or deemed to have been issued) pursuant to
Section 2.1(b)(iv) by the Company after the Commencement Date other than: 
 (a) Common Stock issued pursuant to a
transaction described in Section 2.1(c) hereof; 
  

 Page 7 

 (b) Common Stock issuable or issued from time to time to employees, consultants, officers
or directors of the Company (or of any affiliate of the Company) pursuant to the Company’s 2000 Equity Incentive Plan or pursuant to any other plan to the extent that such issuance is approved by the Board of Directors of the Company;

 (c) Common Stock or Preferred Stock of the Company issued pursuant to the conversion or exercise of convertible or
exercisable securities outstanding as of the Commencement Date, including without limitation, options, warrants, notes or other rights to acquire Common Stork or Preferred Stock; 

(d) Series C Preferred Stock of the Company issued, or issuable upon exercise of warrants to purchase Series C Preferred Stock
of the Company issued in connection with the issuance and sale of Series C Preferred Stock of the Company, or issued after the Commencement Date for consideration per share at least equal to the Series C Conversion Price (as defined in the
Company’s Certificate of Incorporation in effect as of the date hereof); and 
 (e) Capital stock, or options or warrants
to purchase capital stock, issued pursuant to or in connection with any of the following transactions or arrangements, the terms of which are approved by the Board of Directors of the Company; (1) commercial credit arrangements, equipment
financings or similar transactions; (2) bona fide acquisitions, mergers or similar transactions in which such capital stock, or options or warrants to purchase capital stock, are issued for consideration other than cash; and
(3) transactions involving issuances to customers, vendors or strategic, partners of the Company. 
 “Liquidity
Event” shall mean the occurrence of either (a) a transaction or series of transactions (whether structured as a stock sale, merger, consolidation, reorganization, asset sale or otherwise) which results in the sale or transfer of more
than a majority of the assets of the Company and its subsidiaries (determined based on value) or a majority of the capital stock of the Company; or (b) an underwritten public offering of the Common Stock pursuant to an effective registration
statement filed with the Securities and Exchange Commission (but expressly excluding registration statement no. 333-152512) which yields at least $50,000,000 of net cash proceeds to the Company. 

8.2 Expiration. This Warrant shall expire at the close of business on the date five (5) years from the date hereof.

 8.3 Restrictive Legend. This Warrant, any Warrant issued upon transfer of this Warrant and the shares of Common Stock
issued upon exercise of this Warrant shall be imprinted with substantially the following legend, in addition to any legends required under applicable state securities laws: 

“THE SECURITIES REPRESENTED BY THIS [WARRANT CERTIFICATE] HAVE NOT BEEN REGISTERED UNDER THE

  

 Page 8 

 
SECURITIES ACT OF 1933 (THE “ACT”) OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR
OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT
THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS.” 
 8.4 No Voting Rights.
Nothing contained in this Warrant shall be construed as conferring upon Holder by virtue of holding this Warrant (i) the right to vote or to consent as a shareholder in respect of meetings of shareholders for the election of directors of the
Company or any other matter, (ii) the right to receive dividends or (iii) any other rights as a shareholder of the Company. 

8.5 Compliance with Securities Laws. Holder agrees to exercise and transfer (to the extent permitted pursuant to Section 7
hereof) this Warrant in compliance with all applicable federal and state securities laws and agrees to cooperate with the Company in taking any and all action which may be deemed necessary or desirable to ensure such compliance, including, without
limitation, the execution and delivery of one or more documents as requested by the Company representing as to certain matters and acknowledging the restricted nature of the Common Stock to be issued. 

8.6 Modification And Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement is sought. 
 8.7 Saturdays, Sundays, Holidays, etc.
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next
succeeding day not a Saturday or a Sunday or a legal holiday. 
 8.8 Successors and Assigns. This Warrant shall be
binding upon any successors or assigns of the Company. 
 8.9 Notices. All notices, requests, consents and demands with
respect to this Warrant shall be made in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the
recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at 2251 Rutherford Road, 

 

 Page 9 

 
Carlsbad, CA 92008, and to Holder at the applicable address set forth on the applicable signature page to the Subscription Agreement or at such other address as the Company or Holder may
designate by ten (10) days advance written notice to the other parties hereto. 
 8.10 Governing Law. This Warrant
shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of California, without regard to its principles of choice of law. 

(Signature Page Follows) 
  

 Page 10 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed and issued by its duly authorized
representative on the date first above written. 
  

			
	AUTOGENOMICS, INC.
		
	By:	 	  

		 	Fareed Kureshy,
		 	Its President and CEO

 (Signature
Page to Warrant) 

 EXHIBIT I 

FORM OF NOTICE OF EXERCISE 

(To be signed only upon exercise of this Warrant) 

The undersigned, the Holder of the within Warrant, hereby irrevocably elects to exercise such Warrant to purchase
                                         
                    (                    ) shares of
the Company’s common stock, no par value, for a purchase price of
                                         Dollars
($            ) per share and a total purchase price of
                                         Dollars
($            ), to be paid by (check one): 

                    
certified or official bank check; or 

                     wire
transfer. 
 The undersigned is acquiring such shares of stock for its own account for investment purposes only and not with a
view to or for sale in connection with any distribution thereof. 
  

							
	Dated:	 	  
	 		 	  

		 		 		 	 Name of Holder (must conform precisely

to the name specified on the face of the Warrant)

				
		 		 		 	  

		 		 		 	Signature of authorized representative of Holder
				
		 		 		 	  

		 		 		 	Print or type name of authorized representative
				
		 		 	Federal Identification Number of Holder:	 	  

				
		 		 	Address of Holder:	 	  

				
		 		 		 	  

				
		 		 	Telephone Number:	 	  

				
		 		 	Facsimile Number:	 	  

				
		 		 	Email Address:	 	  

 EXHIBIT II 

ASSIGNMENT FORM 
 FOR VALUE
RECEIVED,
                                         
                    hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant with respect to the number and kind
of shares covered thereby set forth below, unto: 
  

							
		 		 	Name of Assignee:	 	  

				
		 		 	Address:	 	  

				
		 		 		 	  

				
		 		 	Telephone Number:	 	  

				
		 		 	Facsimile Number:	 	  

				
		 		 	Email Address:	 	  

				
		 		 	Number and Kind of Shares:	 	  

				
		 		 		 	  

									
					
	Dated:	 	  
	 		 	*Signature:	 	  

  

	*	The signature should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with membership in an
approved signature guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934. 

  

	
	Signature Guaranteed: Title of Organization:
	
	  

 

									
		 		 		 		 	  

					
		 	Dated:	 	  
	 	By:	 	  

					
		 		 		 	Name of Authorized Signatory:	 	  

					
		 		 		 	Title of Authorized Signatory:Form of Subordinated Promissory Note

 Exhibit 10.15 

THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ALL APPLICABLE
STATE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS. 

AUTOGENOMICS, INC. 

6.0% SUBORDINATED NOTE 
  

			
	No.             	  	Vista, California
	$            	  	March     , 2010

FOR VALUE RECEIVED, AutoGenomics, Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of
                                         
                    or registered assigns (“Holder”), the principal amount of
$            , together with interest thereon at the rate of six percent (6.0%) per annum based on a 365-day year and the number of days elapsed, on or before
                    , 2012 (the “Maturity Date”), subject to the terms and conditions set forth below. This 6.0% Subordinated Note
(this “Note”) has been issued pursuant to that certain Subscription Agreement dated                     , 2010, to which the Company
and Holder are parties (the “Agreement”). Capitalized terms not defined herein have the meaning assigned to them in the Agreement. 

This Note is one of a series of 6.0% Subordinated Notes, due 2012, issued in one or more closings (collectively referred to herein as the
“Subordinated Notes”), all of like tenor, except as to the identifying number, principal amount, issue date and holder thereof. 

1. Defined Terms. 

“Affiliate” means, with regard to any Person, (i) any Person, directly or indirectly, controlled by, under common
control with, or controlling such Person, (ii) any Person, directly or indirectly, in which such Person holds, of record or beneficially, five percent (5.0%) or more of the equity or voting securities, (iii) any Person that holds, of
record or beneficially, five percent (5.0%) or more of the equity or voting securities of such Person, (iv) any Person that, through contract, relationship or otherwise, exerts a substantial influence on the management of such
Person’s affairs, (v) any director, officer, partner or individual holding a similar position in respect of such Person, or (vi) as to any natural Person, any Person related by blood, marriage or adoption and any Person owned by such
Persons. 
  

 A-1 

 “Indebtedness” means: 

(i) all indebtedness of the Company for monies borrowed from banks, trust companies, insurance companies and other
financial institutions, including commercial paper, letters of credit and accounts receivable sold or assigned by the Company to such institutions; 

(ii) all indebtedness of the Company for monies borrowed by the Company from other persons or entities (excluding accrued
expenses, trade payables, workers’ compensation claims, self-insurance obligations, bankers’ acceptances, performance, hedging obligations and surety bonds in the ordinary course of business); 

(iii) obligations of the Company as lessee under leases of real or personal property; 

(iv) indebtedness or obligations of others of the kinds described above assumed or guaranteed in any manner by the
Company; 
 (v) deferrals, renewals, extensions and refundings of any such indebtedness or obligations described
above; 
 (vi) any balance deferred and unpaid of the purchase price of any property or services due more than
six months after such property is acquired or such services are completed; and 
 (vii) any other indebtedness of
the Company which the Company and the holders of more than 50% of the unpaid principal amount of the Subordinated Notes then outstanding may hereafter from time to time expressly and specifically agree in writing shall constitute Indebtedness;

 if and to the extent any of the preceding items (other than letters of credit and hedging obligations) would appear as a liability upon a
balance sheet of the specified person prepared in accordance with generally accepted accounting principals, whether or not contingent. In addition, the term “Indebtedness” includes all Indebtedness of others secured by a Lien on any asset
of the Company (whether or not such Indebtedness is assumed by the Company). 
 “Lien” means with respect to
any assets, any mortgage, lien, pledge, charge, security interest or other similar encumbrance (including, without limitation, any conditional sale or other title retention agreement or lease in the nature thereof, any option or other agreement to
sell, and any filing of or agreement to give, any security interest). 
 “Pari Passu Subordinated Notes” means
the Subordinated Notes and all other indebtedness of the Company represented by subordinated promissory notes ranking pari passu with and equal in right of payment to the Subordinated Notes. 

 

 A-2 

 “Person” means any corporation, partnership, joint venture, limited
liability company, organization, entity, governmental authority, body or agency, or natural person. 
 “Senior
Indebtedness” means any (i) Indebtedness designated by the Company as ranking senior to the Subordinated Notes and (ii) any other indebtedness of the Company which the Company and the holders of more than 50% of the unpaid
principal amount of the Subordinated Notes then outstanding may hereafter from time to time expressly and specifically agree in writing shall constitute Senior Indebtedness, provided, however, that (a) the aggregate amount of all Senior
Indebtedness at any one time outstanding shall not exceed $4.0 million; and (b) the Company agrees to provide to the Holder, if requested, the names of the holders of all Senior Indebtedness in writing, and to provide the Holder, if requested,
with copies of all agreements related to any such Senior Indebtedness. Notwithstanding the foregoing, “Senior Indebtedness” shall not include (x) any other Indebtedness of the Company designated as subordinated indebtedness, including
the other Subordinated Notes, which shall rank equally and ratably with or subordinate to the Subordinated Notes, or (y) any Indebtedness of the Company owed to any Affiliate of the Company. 

2. Subordination. 

(a) Subordination to Senior Indebtedness. The Indebtedness evidenced by this Note, and the payment of the principal hereof and
interest hereon, (i) is wholly subordinated, junior and subject in right of payment, to the extent and in the manner hereinafter provided, to the prior payment of all Senior Indebtedness and (ii) ranks pari passu in right of
payment to all other indebtedness of the Company represented by subordinated promissory notes outstanding on the date hereof. 

(b) Rights of Holders Unimpaired. The provisions of this Section 2 are, and are intended solely, for the purposes of defining
the relative rights of the holders of the Subordinated Notes and the holders of Senior Indebtedness and nothing in this Section 2 shall impair, as between the Company and any holders of the Subordinated Notes, the obligation of the Company,
which is unconditional and absolute, to pay to the holders of the Subordinated Notes the principal thereof, in accordance with the terms of the Subordinated Notes, nor shall anything herein prevent any holders of the Subordinated Notes from
exercising all remedies otherwise permitted by applicable law or hereunder upon default, subject to the rights set forth above of holders of Senior Indebtedness to receive cash, property or securities otherwise payable or deliverable to the holders
of the Subordinated Notes. 
 3. Repayment of the Subordinated Notes. 

(a) Repayment at the Maturity Date. On the Maturity Date, the Company shall repay all, but not less than all, of the outstanding
principal amount of the Subordinated Notes due on such Maturity Date, and all accrued and unpaid interest thereon, by mailing a corporate check in such amount payable to the Holder at the Holder’s address of record as contained herein, or on
file with the Company pursuant to notice given as provided herein, no later than ten (10) business days after the Maturity Date or, at the request of the Holder, by wire transfer of immediately available funds designated in writing by the
Holder. 
  

 A-3 

 (b) Redemption Prior to the Maturity Date. The Company may redeem in whole or in part
the Note, at any time or from time to time, without penalty at a redemption price equal to 100% of the principal amount of Note, together with all accrued and unpaid interest thereon through the redemption date, provided that such redemption
is on a pro rata basis with all other Subordinated Notes then outstanding (determined based on the aggregate principal amount of all Subordinated Notes then outstanding as of such redemption date). 

(c) Cancellation of Subordinated Note. Immediately upon repayment in full of this Note, including all principal, accrued interest,
redemption price, as applicable, and any amounts owed pursuant to paragraph 9(e) hereof, this Note shall no longer be deemed to be outstanding and all rights with respect to this Note shall immediately cease and terminate as of the date of such
repayment. 
 4. Covenants of the Company. 

(a) Incurrence of Additional Indebtedness. The Company shall not incur any Indebtedness after the date hereof without the prior
written consent of holders representing 75% of the aggregate principal amount of all then outstanding Pari Passu Subordinated Notes; provided, however, that without the consent of any of the holders of the Subordinated Notes, the Company may
incur: 
 (1) equipment financing, receivables-based financing and unsecured Indebtedness, in an aggregate principal amount
and/or aggregate borrowing capacity not to exceed $4.0 million at any one time outstanding, including any refinancings or replacements thereof, and 

(2) refinancing of Indebtedness outstanding as of the date hereof (which for the avoidance of doubt shall include the Subordinated
Notes), provided that (i) the principal amount of the refinancing indebtedness incurred pursuant to this clause (2) is not greater than the principal amount of the Indebtedness being refinanced, and (ii) the maturity date of
the refinancing indebtedness is not prior to the maturity date of the Indebtedness being refinanced. 
 The Company may
designate, at the time of incurrence, that Indebtedness incurred pursuant to this Section 4(a) may be incurred in whole or in part under either of clause (1) or (2), and may be redesignated from time to time at the Company’s sole and
absolute discretion. 
 (b) Reports. Until the Company becomes subject to the reporting requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, at the request of the Holder, the Company agrees to furnish to the Holder the following financial statements and other information: 

(1) as soon as available, copies of the unaudited consolidated balance sheets of the Company and its subsidiaries as of
the end of the first three quarterly accounting periods during the fiscal year of the Company in which the Holder makes such request, and of the related consolidated statements of income and retained earnings and cash flows for such accounting
periods; 
  

 A-4 

 (2) as soon as available after the end of each fiscal year of the Company,
copies of the audited consolidated balance sheets of the Company and its subsidiaries as of the end of such fiscal year, and of the related audited consolidated statements of income and retained earnings and cash flows for such fiscal year
accompanied by a report thereon from independent certified public accountants selected by the Company; provided that the Company shall not be required to deliver audited financial statements if not otherwise required in connection with its
financing agreements. 
 (c) Terms No More Favorable. If any of the other subordinated indebtedness issued by the Company
after the date hereof contain terms more favorable to the holder of such subordinated indebtedness than those contained in this Note (such subordinated indebtedness, the “More Favorable Terms Note”), the Company shall promptly (but
not less than 5 days after the issuance of such More Favorable Terms Note) offer to exchange for this Note a new Subordinated Note which shall have the same terms as this Note plus the more favorable terms of the More Favorable Terms Note.

 5. Requirements for Transfer. This Note shall not be sold or transferred unless either (i) this Note shall have
been registered or qualified under the Securities Act of 1933, as amended (the “Act”), and all applicable state securities laws with respect thereto or (ii) the Company first shall have been furnished with an opinion of legal
counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration or qualification requirements of the Act and all applicable state securities laws with respect thereto. 

6. Payment of Principal. All payments due and payable from the Company to Holder under this Note shall be made in lawful currency
of the United States of America. In no event shall any prepayment of principal be made with respect to any other subordinated indebtedness of the Company unless and until the Company shall have concurrently prepaid a like proportionate amount of the
principal of this Note. All repayments and prepayments under this Note shall be applied first to accrued and unpaid interest and then to the outstanding principal balance hereof. 

7. Default. Upon the occurrence of an Event of Default (as defined below), the entire unpaid portion of the principal amount of
this Note, and all accrued and unpaid interest due Holder hereunder, shall automatically become due and payable. As used in this Note, “Event of Default” shall mean: (i) a receiver, trustee, custodian or similar officer is appointed
for the Company, or for any substantial part of its property and such appointment or proceedings remain unstayed or undismissed for a period of 90 days, (ii) any bankruptcy, insolvency, reorganization, arrangement, readjustment of debt,
dissolution, liquidation or similar proceedings under the laws of any jurisdiction is instituted (by petition, application or otherwise) against the Company and such appointment or proceedings remain unstayed or undismissed for a period of 90 days,
(iii) the Company admits in writing its inability to pay its debts when due, (iv) the Company makes an assignment for the benefit of creditors, (v) the Company applies for or consents to the appointment of any receiver, trustee,
custodian or similar officer for the Company or for any substantial part of its property, (vi) the Company institutes (by petition, application or otherwise) or consents to any bankruptcy, insolvency, reorganization, arrangement, readjustment
of debt, dissolution, liquidation or similar proceedings under the laws of any jurisdiction against 
  

 A-5 

 
the Company, (vii) any Indebtedness of the Company in excess of $1,000,000 is accelerated prior to its scheduled maturity date, (viii) the Company fails to make any principal or
interest payment under this Note when due and, other than at scheduled maturity, such breach remains uncured for 10 days following written notice from any holder of Subordinated Notes, and (ix) the Company breaches any of its other obligations
hereunder or as set forth in the Agreement and such breach remains uncured for thirty days following written notice from any holder of Subordinated Notes. 

8. Replacement. Whenever this Note shall be surrendered at the principal executive office of the Company for transfer or exchange,
accompanied by a written instrument of transfer in form reasonably satisfactory to the Company duly executed by the Holder hereof or his, her or its attorney duly authorized in writing, the Company shall execute and deliver in exchange therefor a
new Note or Notes, as may be requested by such Holder, in the same aggregate unpaid principal amount and payable on the same date as the principal amount of the Note or Notes so surrendered; each such new Note shall be in such principal amount and
registered in such name or names as such Holder may designate in writing. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note and of indemnity reasonably satisfactory to
it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of this Note (in case of mutilation) the Company will make and deliver in lieu of this Note a new Note of like tenor and
unpaid principal amount. 
 9. General. 

(a) Successors and Assigns. This Note, and the obligations and rights of the Company hereunder, shall be binding upon and inure to
the benefit of the Company, the Holder of this Note, and their respective heirs, successors and assigns. 
 (b) Notices.
All notices, requests, consents and demands shall be made in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal
business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at 2980 Scott Street, Vista, CA 92801, Attention: President, and to the Holder at the applicable
address set forth on the applicable signature page to the Subscription Agreement or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. 

(c) Governing Law. This Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed
by, the laws of the State of New York, without regard to its principles of choice of law. 
 (d) Waiver and Amendment. No
delay or omission on the part of the Holder in exercising any right under this Note shall operate as a waiver of such right or of any other right of such Holder, nor shall any delay, omission or waiver on any one occasion be deemed a

  

 A-6 

 
bar to or waiver of the same or any other right on any future occasion. The Company hereby waives presentment, notice of dishonor, protest and notice of protest with respect to this Note. This
Note may only be amended or modified by a written agreement signed by the Company and Holder. 
 (e) Costs of Collection.
The Company agrees to pay on demand all costs of collection, including reasonable attorney’s fees, incurred by the Holder in enforcing the obligations of the Company under this Note. 

(f) Confidentiality. By the Holder’s acceptance hereof, the Holder agrees to keep confidential and not disclose, divulge or
use for any unauthorized purpose any confidential, proprietary or secret information which the Holder may obtain from the Company and which is marked by the Company as confidential (i) pursuant to financial statements, reports and other
materials submitted by the Company to the Holder, or (ii) pursuant to visitation or inspection rights (if any) granted to the Holder, in each case, unless such information is known, or until such information becomes known, to the public, or the
Holder is required by any governmental agency, court or other regulatory body having jurisdiction over the Holder to disclose such information, but only for the sole purpose of and solely to the extent required by such agency, court or other
regulatory body, provided that the Holder, to the extent possible, shall give the Company prior written notice of the proposed disclosure and cooperate fully with the Company to minimize the scope of any such required disclosure, to the
extent possible and in accordance with applicable law. 
 (g) Headings. The headings in this Note are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Note. 
 (Signature Page
Follows) 
  

 A-7 

 IN WITNESS WHEREOF, this Note has been executed and delivered on the date first above
written by the undersigned authorized representative of the Company. 
  

			
	AUTOGENOMICS, INC.
	a Delaware corporation
		
	By:	 	  

		 	Fareed Kureshy
		 	President and CEO

 (Signature Page to
Subordinated Note)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]